Published in
Elsevier, European Journal of Cancer, (130), p. 219-227, 2020
DOI: 10.1016/j.ejca.2020.01.026
Links
Tools
Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer
Journal article published in 2020 by
Richard D. Kim,
Shannon McDonough,
Anthony B. El-Khoueiry,
Tanios S. Bekaii-Saab,
Stacey M. Stein,
Vaibhav Sahai 
,
George P. Keogh,
Edward J. Kim ,
Ari D. Baron ,
Abby B. Siegel,
Afsaneh Barzi,
Katherine A. Guthrie ,
Milind Javle,
Howard Hochster
,
George P. Keogh,
Edward J. Kim ,
Ari D. Baron ,
Abby B. Siegel,
Afsaneh Barzi,
Katherine A. Guthrie ,
Milind Javle,
Howard Hochster
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 